A Phase 1 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab in Patients With Advanced Solid Malignancies

Trial Profile

A Phase 1 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab in Patients With Advanced Solid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Evofosfamide (Primary) ; Ipilimumab (Primary)
  • Indications Head and neck cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Threshold Pharmaceuticals
  • Most Recent Events

    • 13 Jun 2017 According to a Threshold Pharmaceuticals media release, first patient has been dosed in the trial at the University of Texas MD Anderson Cancer Center.
    • 10 May 2017 Status changed from not yet recruiting to recruiting.
    • 27 Mar 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top